Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis arising from colorectal cancer. Issue 7 (9th September 2013)

• Record Type: Journal Article
• Authors: Gervais, Mai‐Kim; Dubé, Pierre; McConnell, Yarrow; Drolet, Pierre; Mitchell, Andrew; Sideris, Lucas
• Is Part Of: Journal of surgical oncology. Volume 108:Issue 7(2013:Dec. 01)
• Page Start: 438
• Page End: 443
• Publication Date: 2013-09-09
• Subjects: Cancer -- Surgery -- Periodicals; Neoplasms -- Periodicals; 616
• DOI: 10.1002/jso.23431
• Languages: English
• ISSNs: 0022-4790

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <sec id="jso23431-sec-0001" sec-type="section"> <title>Background</title> <p>Peritoneal carcinomatosis (PC) from colorectal cancer is associated with a poor prognosis. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) have improved survival compared to systemic chemotherapy. We evaluate the results of this treatment in our institution.</p> </sec> <sec id="jso23431-sec-0002" sec-type="section"> <title>Methods</title> <p>Treatment consisted of complete CRS followed by HIPEC with oxaliplatin (460 mg/m<sup>2</sup>) in 2 L/m<sup>2</sup> of D5W at 42°C during 30 min.</p> </sec> <sec id="jso23431-sec-0003" sec-type="section"> <title>Results</title> <p>From 2004 to 2011, 40 patients with PC from colorectal cancer were included and 25 CRS + HIPEC were performed. Six patients had a negative second‐look surgery and nine had unresectable disease. Median follow‐up was 22.8 months. Overall 3‐ and 5‐year survival rates for the cohort were 56% and 33%. The 3‐ and 5‐year overall survival rates were 61% and 36% for HIPEC group, 82% and 67% for patients with negative second‐look, and 22% and 0% for the unresectable group (<italic>P</italic> = 0.0087). 3‐year disease‐free survival for HIPEC group was 22%. Major complication and mortality rate for HIPEC group were 20% and 4%. Peritoneal carcinomatosis index (<italic>P</italic> = 0.0374) and lymph node status (<italic>P</italic> = 0.027) were prognostic indicators.</p> </sec> <sec id="jso23431-sec-0004" sec-type="section"> <title>Conclusions</title> <p>CRS + HIPEC with oxaliplatin for PC from colorectal cancer is an effective treatment with encouraging survival results. <italic>J. Surg. Oncol. 2013; 108:438–443</italic>. © 2013 Wiley Periodicals, Inc.</p> </sec> </abstract>